HMB-003: HMB-003 will be administered subcutaneously as a single dose
Placebo: Placebo will be administered subcutaneously as a single dose of placebo.
Study summary
The purposes of this clinical study are
1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects.
2. To measure the amount of HMB-003 in the body after injection.
Eligibility
Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.
* Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.
Exclusion Criteria:
* Participant has a history of clinically significant hypersensitivity to any excipients of the study drug
* Participant is pregnant, breastfeeding, or \<6 weeks postpartum.
* Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.
Primary outcome measure(s)
Number of participants with treatment emergent adverse events (TEAEs) — From Day 1 up to 42 days after a single dose of study drug on Day 1
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.